此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma

2026年6月17日 更新者：Institut Paoli-Calmettes

Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma: Identification of New Therapeutic Targets

The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers.

Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

Pancreatic adenocarcinoma (PDAC) remains one of the deadliest cancers, with survival rarely exceeding a few months and limited progress despite improved chemotherapy. Its poor prognosis is driven by late diagnosis, therapeutic resistance, and low responsiveness to targeted therapies and immunotherapy.

PDAC is characterized by a dense, immunosuppressive stroma and severe metabolic stress due to poor vascularization. Tumor progression relies heavily on stromal cells-such as cancer-associated fibroblasts and macrophages-as well as metabolic adaptations of cancer cells.

This project focuses on two key PDAC features to identify new biomarkers and therapeutic targets:

  • Stromal cell prevalence
  • Metabolic reprogramming

研究类型

观察性的

注册 (估计的)

64

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 法国
      • Marseille、法国、13009
        • 招聘中
        • Institut Paoli-Calmettes
        • 接触：

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

The study population will include adult men and women (≥18 years) diagnosed with metastatic pancreatic adenocarcinom

描述

Inclusion Criteria:

  1. Age > 18 years
  2. Signed written informed consent specific to the PROMETAP study
  3. Affiliation with a social security system
  4. Treatment and follow-up performed at the Institut Paoli-Calmettes
  5. Metastatic PDAC requiring biopsy as part of routine care (group1 and 2)

  6. Prior treatment:

    • No previous chemotherapy for the "initial" group
    • No prior chemotherapy in the metastatic setting for the "Metastatic Relapse" group
  7. Eligible for chemotherapy (ECOG < 2)

Non-Inclusion Criteria:

  1. Contraindication to biopsy of the pancreatic tumor or a hepatic or pulmonary metastasis (group 1 and 2)
  2. Absence of a metastasis accessible to biopsy (group1 and 2)
  3. Concurrent treatment for another active cancer
  4. Pregnant or breastfeeding women
  5. Patients in emergency situations

5. Adult individuals under legal protection (guardianship, trusteeship, judicial protection) or unable to provide informed consent

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

队列和干预

团体/队列
干预/治疗
Groupe 1-Initial
Paired pancreatic and liver/lung metastatic biopsies will be used to establish primary and metastatic cell cultures from tumor specimens obtained during routine diagnostic procedures, along with peripheral blood samples, in a cohort of 12 patients
其他：Biopsy collection
Tumor cells isolation
其他：Blood collection
Isolation of blood monocytes
Group 2- Relapse
Biopsies of liver or lung metastases obtained at metastatic relapse or progression, along with peripheral blood samples, will be required from 12 patients for the establishment of primary and metastatic cell cultures.
其他：Biopsy collection
Tumor cells isolation
其他：Blood collection
Isolation of blood monocytes
Group 3- Biological
40 patient samples collected before chemotherapy and paired samples collected during chemotherapy will support molecular and cellular analyses aimed at identifying and assessing novel biomarkers and therapeutic strategies
其他：Blood collection
Isolation of blood monocytes

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Evaluation and comparison of biological parameters reflecting metabolic alterations within the tumor microenvironment of pancreatic adenocarcinoma
大体时间：From sample collection to completion of analyses, estimated at 3 years
  • Assessment of stromal dependency mechanisms;
  • Characterization and comparison of the metabolic profiles of primary pancreatic tumors and associated liver and lung metastases.

These analyses aim to identify potential therapeutic targets and to explore diagnostic, prognostic, and predictive biomarkers of treatment response.
From sample collection to completion of analyses, estimated at 3 years

次要结果测量

结果测量
措施说明
大体时间
Exploratory characterization of metabolic pathways, tumor microenvironment features, and associated biomarkers in pancreatic adenocarcinoma.
大体时间：From sample collection to completion of analyses, estimated at 3 years
  • Identification of prognostic markers of therapeutic response originating from the tumor microenvironment.
  • Identification of mechanisms of resistance to anti-tumor treatments linked to the microenvironment.
  • Identification of new therapeutic strategies capable of specifically targeting the tumor microenvironment.
From sample collection to completion of analyses, estimated at 3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Institut Paoli-Calmettes

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月11日

初级完成 (估计的)

2028年9月1日

研究完成 (估计的)

2028年9月1日

研究注册日期

首次提交

2026年3月30日

首先提交符合 QC 标准的

2026年6月17日

首次发布 (实际的)

2026年6月24日

研究记录更新

最后更新发布 (实际的)

2026年6月24日

上次提交的符合 QC 标准的更新

2026年6月17日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • PROMETAP-IPC 2022-048

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅